NCT02498769View on ClinicalTrials.gov

Temporary Autonomic Blockade to Prevent Atrial Fibrillation After Cardiac Surgery

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

130

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

September 28, 2017

Study Completion Date

December 1, 2018

Conditions
Atrial Fibrillation
Interventions
DRUG

Botulinum Toxin Type A

The botulinum toxin will be injected into epicardial fat pads shortly after cardiopulmonary bypass is initiated.

DRUG

Placebo

Trial Locations (1)

27710

Duke University Medical Center, Durham

All Listed Sponsors
collaborator

Foundation for Anesthesia Education and Research

OTHER

collaborator

American Heart Association

OTHER

lead

Joseph Mathew, M.D.

OTHER

NCT02498769 - Temporary Autonomic Blockade to Prevent Atrial Fibrillation After Cardiac Surgery | Biotech Hunter | Biotech Hunter